

2019 State Profile — Pennsylvania

National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients (collected every other year) in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2019 N-SSATS report:

<https://www.samhsa.gov/data/data-we-collect/n-ssats-national-survey-substance-abuse-treatment-services>

In Pennsylvania, 600 substance abuse treatment facilities were included in the 2019 N-SSATS report, which reported a total of 66,969 clients in substance abuse treatment on March 29, 2019. The survey response rate in Pennsylvania was 95.3 percent.

Facility operation, by number and percent

	Clients in treatment on March 29, 2019					
	Facilities		All clients		Clients under the age of 18 years	
	No.	%	No.	%	No.	%
Private non-profit	329	54.8	30,399	45.4	1,818	72.9
Private for-profit	258	43.0	34,202	51.1	677	27.1
Local, county, or community government	2	0.3	520	0.8	—	—
State government	2	0.3	81	0.1	—	—
Federal government	9	1.5	1,767	2.6	—	—
Tribal government	—	—	—	—	—	—
Total	600	100.0	66,969	100.0	2,495	100.0

Note: Percentages may not sum to 100 percent due to rounding.

Substance abuse problem treated, by number and percent

	Clients in treatment on March 29, 2019				
	Facilities ¹		Clients ²		Clients ² per 100,000 pop. aged 18 years or older
	No.	%	No.	%	
Clients with both alcohol and drug abuse	419	87.5	18,930	29.4	174
Clients with drug abuse only	433	90.4	38,546	59.8	370
Clients with alcohol abuse only	377	78.7	6,977	10.8	65
Total			64,453	100.0	610

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Facility capacity and utilization rate¹

	Residential	Hospital inpatient
Number of facilities	119	14
Number of clients ²	5,691	614
Number of designated beds	5,650	688
Utilization rate ³	100.7	89.2
Average number of designated beds per facility	47	49

¹ Excludes facilities not reporting both client counts and number of beds, facilities whose client counts were reported by another facility, facilities that included client counts from other facilities, and facilities that did not respond to this question.

² Number of clients on March 29, 2019.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

For a symbol key, see the last page of this profile.

Type of care, by number and percent

	Clients in treatment on March 29, 2019							
	Facilities		All clients				Clients under the age of 18 years	
	No.	%	No.	%	Median no. of	Median no. of	No.	%
					clients per	clients per		
OTP facility	non-OTP facility							
Outpatient	461	76.8	60,407	90.2	330	73	1,666	66.8
Regular	433	72.2	23,330	34.8	59	44		
Intensive	316	52.7	6,893	10.3	35	20		
Day treatment or partial hospitalization	105	17.5	1,660	2.5	21	10		
Detoxification	41	6.8	230	0.3	8	3		
Methadone/buprenorphine maintenance or naltrexone treatment	230	38.3	28,294	42.2	309	19		
Residential (non-hospital)	159	26.5	5,894	8.8	33	24	828	33.2
Short term (≤ 30 days)	103	17.2	2,976	4.4	31	18		
Long term (> 30 days)	126	21.0	2,311	3.5	32	19		
Detoxification	56	9.3	607	0.9	4	8		
Hospital inpatient	27	4.5	668	1.0	15	11	1	*
Treatment	18	3.0	392	0.6	20	8		
Detoxification	25	4.2	276	0.4	14	8		
Total	600		66,969	100.0	273	52	2,495	100.0

Note: Facilities may provide more than one type of care.

Facility licensing, certification, or accreditation, by number and percent

	No.	%
Any listed agency/organization	584	97.3
State substance abuse agency	532	88.7
State mental health department	132	22.0
State department of health	388	64.7
Hospital licensing authority	28	4.7
The Joint Commission	126	21.0
Commission on Accreditation of Rehabilitation Facilities (CARF)	185	30.8
National Committee for Quality Assurance (NCQA)	10	1.7
Council on Accreditation (COA)	16	2.7
Healthcare Facilities Accreditation Program (HFAP)	2	0.3
Other national organization or federal, state, or local agency	16	2.7

Note: Facilities may be licensed, certified, or accredited by more than one agency/organization.

Facility payment options, by number and percent

	No.	%
Cash or self-payment	543	90.5
Private health insurance	444	74.0
Medicare	168	28.0
Medicaid	503	83.8
State-financed health insurance plan other than Medicaid	297	49.5
Federal military insurance	130	21.7
No payment accepted (free treatment for all clients)	1	0.2
IHS/Tribal/Urban (ITU) funds	9	1.5
Other	2	0.3
Sliding fee scale	271	45.2
Treatment at no charge or minimal payment for clients who can't pay	201	33.5

Note: Facilities may accept more than one type of payment.

Types of services offered, by number and percent

	Facilities	
	No.	%
Assessment and pre-treatment services		
Screening for substance abuse	577	96.2
Screening for mental health disorders	411	68.5
Comprehensive substance abuse assessment or diagnosis	559	93.2
Comprehensive mental health assessment or diagnosis	256	42.7
Screening for tobacco use	458	76.3
Outreach to persons in the community who may need treatment	384	64.0
Interim services for clients when immediate admission is not possible	268	44.7
Professional interventionist/educational consultant	56	9.3
None of these assessment and pre-treatment services offered	7	1.2
Testing		
Drug and alcohol oral fluid testing	138	23.0
Breathalyzer or other blood alcohol testing	385	64.2
Drug or alcohol urine screening	550	91.7
Testing for hepatitis B	166	27.7
Testing for hepatitis C	218	36.3
HIV testing	188	31.3
STD testing	146	24.3
TB screening	275	45.8
Testing for metabolic syndrome	56	9.3
None of these testing services offered	38	6.3
Medical services		
Hepatitis A (HAV) vaccination	25	4.2
Hepatitis B (HBV) vaccination	31	5.2
None of these medical services offered	567	94.5
Transitional services		
Discharge planning	593	98.8
Aftercare/continuing care	568	94.7
Naloxone and overdose education	450	75.0
Outcome follow-up after discharge	541	90.2
None of these transitional services offered	3	0.5
Recovery support services		
Mentoring/peer support	368	61.3
Self-help groups (for example, AA, NA, SMART Recovery)	328	54.7
Assistance in locating housing for clients	397	66.2
Employment counseling or training for clients	240	40.0
Assistance with obtaining social services (for example, Medicaid, WIC, SSI, SSDI)	469	78.2
Recovery coach	91	15.2
None of these recovery support services offered	54	9.0
Education and counseling services		
HIV or AIDS education, counseling, or support	339	56.5
Hepatitis education, counseling, or support	334	55.7
Health education other than HIV/AIDS or hepatitis	338	56.3
Substance abuse education	590	98.3
Smoking/ tobacco cessation counseling	330	55.0
Individual counseling	590	98.3

Continued

For a symbol key, see the last page of this profile.

Types of services offered, by number and percent (continued)

	Facilities	
	No.	%
Group counseling	563	93.8
Family counseling	554	92.3
Marital/couples counseling	401	66.8
Vocational training or educational support	85	14.2
None of these education and counseling services offered	—	—
Pharmacotherapies		
Disulfiram (Antabuse®)	109	18.2
Naltrexone (oral)	254	42.3
Naltrexone (extended-release, injectable, for example, Vivitrol®)	279	46.5
Acamprosate (Campral®)	120	20.0
Nicotine replacement	180	30.0
Non-nicotine smoking/tobacco cessation medications (for example, bupropion, varenicline)	143	23.8
Medications for psychiatric disorders	288	48.0
Methadone ¹	91	15.2
Buprenorphine with naloxone (for example, Suboxone®, Bunavail®, Zubsolv®, Cassipa®)	251	41.8
Buprenorphine without naloxone	157	26.2
Buprenorphine sub-dermal implant (Probuphine®)	17	2.8
Buprenorphine (extended-release, injectable, for example, Sublocade®)	67	11.2
Medications for HIV treatment (for example, antiretroviral medications such as tenofovir, efavirenz, emtricitabine, atazanavir, and lamivudine)	67	11.2
Medications for hepatitis C (HCV) treatment (for example, sofosbuvir, ledipasvir, interferon, peginterferon, ribavirin)	67	11.2
Lofexidine	8	1.3
Clonidine	105	17.5
None of these pharmacotherapy services offered	167	27.8
Ancillary services		
Case management services	412	68.7
Social skills development	415	69.2
Child care for clients' children	39	6.5
Domestic violence—family or partner violence services (physical, sexual, and emotional abuse)	190	31.7
Early intervention for HIV	136	22.7
Transportation assistance to treatment	305	50.8
Mental health services	329	54.8
Acupuncture	23	3.8
Residential beds for clients' children	14	2.3
None of these ancillary services offered	35	5.8
Other services		
Treatment for gambling disorder	177	29.5
Treatment for Internet use disorder	54	9.0
Treatment for other addiction disorder (non-substance abuse)	181	30.2
None of these 'other' services offered	343	57.2

¹ Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment.

Clinical/therapeutic approaches used frequently, by number and percent

	Facilities	
	No.	%
Substance abuse counseling	596	99.3
12-step facilitation	480	80.0
Brief intervention	504	84.0
Cognitive behavioral therapy	590	98.3
Dialectical behavior therapy	381	63.5
Contingency management/motivational incentives	336	56.0
Motivational interviewing	584	97.3
Trauma-related counseling	514	85.7
Anger management	484	80.7
Matrix model	182	30.3
Community reinforcement plus vouchers	65	10.8
Rational emotive behavioral therapy (REBT)	285	47.5
Relapse prevention	595	99.2
Telemedicine/telehealth	92	15.3
Other treatment approaches	59	9.8
We do not use any of these clinical/therapeutic approaches	—	—

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	506	84.3
Adolescents	133	22.2
Young adults	176	29.3
Adult women	312	52.0
Pregnant or postpartum women	155	25.8
Adult men	290	48.3
Seniors or older adults	134	22.3
LGBT clients	133	22.2
Veterans	113	18.8
Active duty military	59	9.8
Members of military families	58	9.7
Criminal justice clients (other than DUI/DWI)	211	35.2
Clients with co-occurring mental and substance use disorders	304	50.7
Clients with co-occurring pain and substance use	90	15.0
Clients with HIV or AIDS	122	20.3
Clients who have experienced sexual abuse	175	29.2
Clients who have experienced intimate partner violence, domestic violence	163	27.2
Clients who have experienced trauma	264	44.0
DUI/DWI clients	109	18.2
Other	26	4.3
No specifically tailored programs or groups are offered	94	15.7

DUI/DWI = driving under the influence/driving while intoxicated or impaired; LGBT = lesbian, gay, bisexual, or transgender.

Facility funding, by number and percent

	Facilities	
	No.	%
Receives federal, state, county, or local government funds or grants for substance use treatment programs	319	53.2

Services in sign language for the deaf and hard-of-hearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	159	26.5
Any language other than English	228	38.0
Non-English language provided by		
Staff counselor only	70	30.7
On-call interpreter only	120	52.6
Both staff counselor and on-call interpreter	38	16.7
Languages provided by staff counselor¹		
Spanish	101	93.5
American Indian/Alaska Native languages	—	—
Other	26	24.1

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Symbol key (where applicable)

— Quantity is zero; * Less than 0.05 percent;
 † Less than 1 per 100,000; ‡ No facilities in this category.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 29, 2019. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: <https://www.samhsa.gov/data/data-we-collect/n-ssats-national-survey-substance-abuse-treatment-services>

Access the latest N-SSATS public use files at: <https://datafiles.samhsa.gov>

For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at: <https://findtreatment.samhsa.gov/>



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
 Substance Abuse and Mental Health Services Administration
 Center for Behavioral Health Statistics and Quality
www.samhsa.gov/data

Clients receiving medication-assisted opioid therapy (MAOT) at facilities with opioid treatment programs (OTPs) and non-OTP facilities, by number and percent


	No.	%
Facilities with OTPs¹	102	6.0
Clients in facilities with OTPs²		
Any MAT ³	26,166	5.9
Methadone	23,351	5.7
Buprenorphine	2,581	7.3
Naltrexone	234	7.8
Clients in facilities without OTPs⁴		
Any MAT ⁵	4,993	3.1
Buprenorphine	3,841	2.9
Naltrexone	1,152	4.2

¹ Percentage of all facilities with OTPs in the U.S. ² Percentage of all clients receiving methadone, buprenorphine, or naltrexone at facilities with OTPs in the U.S.; see 2019 N-SSATS report for details. ³ Consists of clients receiving methadone, buprenorphine, or naltrexone. ⁴ Percentage of all clients receiving buprenorphine or naltrexone at non-OTP facilities in the U.S.; see 2019 N-SSATS report for details. ⁵ Consists of clients receiving buprenorphine or naltrexone.

Clients per 100,000 population receiving MAOT in OTP facilities on March 29, 2019

	No.
Any type of medication-assisted therapy ¹	204
Methadone	182
Buprenorphine	20
Naltrexone	2

¹ Includes clients receiving methadone, buprenorphine, or naltrexone.

Location of treatment facilities

<https://www.samhsa.gov/data/quick-statistics>